🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,867 results for “De” Clear

  1. cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, Placebo + Placebo, cagrilintide semaglutide

    NovoThirteen

    Overweight and obesity and type 2 diabetes

    phase 3 small molecule active

    1 trial

  2. cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, Placebo + Placebo

    NovoThirteen

    Type 2 diabetes

    phase 3 small molecule active

    1 trial

  3. cagrilintide, Placebo, cagrilintide, cagrilintide, cagrilintide

    NovoThirteen

    Overweight and obesity

    phase 3 small molecule active

    1 trial

  4. cagrilintide, cagrilintide, cagrilintide, cagrilintide, Placebo

    NovoThirteen

    Overweight and obesity

    phase 3 small molecule active

    1 trial

  5. camizestrant, Arimidex® 1 mg Filmtabletten, IBRANCE 75 mg hard capsules, Placebo to match camizestrant, Placebo to match Arimidex, LEUPRORELIN ACETATE, IBRANCE 125 mg hard capsules, IBRANCE 75 mg film-coated tablets, IBRANCE 100 mg hard capsules, IBRANCE 75 mg hard capsules, IBRANCE 100 mg hard capsules, IBRANCE 125 mg film-coated tablets, IBRANCE 100 mg film-coated tablets, IBRANCE 125 mg hard capsules, IBRANCE 100 mg hard capsules, Camizestrant, IBRANCE 125 mg hard capsules, IBRANCE 75 mg hard capsules, G

    AstraZeneca AB

    Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

    phase 3 small molecule active

    1 trial

  6. candesartan

    Takeda

    Type 1 Diabetes

    phase 3 small molecule completed

    1 trial

  7. candesartan

    Takeda

    Type 2 Diabetes

    phase 3 small molecule completed

    1 trial

  8. candesartan cilexetil

    Takeda

    Type 1 Diabetes

    phase 3 small molecule completed

    1 trial

  9. casirivimab+imdevimab

    Regeneron UK Limited

    Immunocompromised

    phase 3 small molecule terminated

    1 trial

  10. casirivimab+imdevimab combination therapy

    Regeneron UK Limited

    COVID-19

    phase 3 small molecule terminated

    1 trial

  11. centrally blinded product containing all the same manufactured ingredients and excipients as the DM199 formulation, except for the active pharmaceutical ingredient (API).

    DiaMedica Therapeutics

    Acute Ischemic Stroke

    phase 3 small molecule active

    1 trial

  12. chemotherapy and SHR-1316(Adebrelimab) comnined with surgery or radiotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Limited Stage Small Cell Lung Cancer

    phase 3 other active

    1 trial

  13. ciclesonide

    Takeda

    Asthma

    phase 3 small molecule completed

    2 trials

  14. ciclesonide (XRP1526)

    Takeda

    Respiratory Tract Diseases

    phase 3 small molecule completed

    1 trial

  15. cisplatin

    United Therapeutics Europe Ltd

    Bladder Cancer

    phase 3 small molecule completed

    1 trial

  16. cisplatin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Oral Cavity

    phase 3 small molecule completed

    1 trial

  17. cisplatin i.p.

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Epithelial Carcinoma, Ovarian

    phase 3 small molecule active

    1 trial

  18. clopidogrel and aspirin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Atherosclerosis

    phase 3 small molecule active

    1 trial

  19. cognitive-behavioral withdrawal regulation strategies

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Dependence

    phase 3 other active

    1 trial

  20. cyclobenzaprine hydrochloride

    Teva Pharma GmbH

    Chronic Migraine

    phase 3 small molecule terminated

    1 trial

  21. cyclophosphamide

    Partner Therapeutics Limited

    Breast Cancer

    phase 3 small molecule completed

    1 trial

  22. daclatasvir

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatitis C

    phase 3 small molecule completed

    1 trial

  23. decitabine

    The First People's Hospital of Lianyungang

    Poor Graft Function

    phase 3 small molecule active

    1 trial

  24. decitabine

    The First People's Hospital of Lianyungang

    Acute Myelocytic Leukemia

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources